Find Th\u00e9rapeutiques a annonc\u00e9 aujourd\u2019hui le d\u00e9but de son \u00e9tude clinique de phase 1 avec l\u2019administration du FTX-101 chez des volontaires sains. FTX-101 est un peptide th\u00e9rapeutique, premier de sa cat\u00e9gorie, qui promouvoit la remy\u00e9linisation dans le cerveau en modulant l\u2019activit\u00e9 du complexe r\u00e9cepteur transmembranaire Plexine A1\/Neuropiline 1. Suite \u00e0 cette \u00e9tude clinique de phase 1, Find pr\u00e9voit d\u2019\u00e9tudier l\u2019utilisation du FTX-101 chez les personnes atteintes de neuropathie optique chronique, une affection de longue dur\u00e9e caus\u00e9e par la demy\u00e9linisation du nerf optique et des voies visuelles du cerveau, avec des effets graves sur l\u2019acuit\u00e9 et la perception visuelles.<\/p>\n\n\n\n
L\u2019\u00e9tude clinique de phase 1, la premi\u00e8re chez l\u2019homme, a \u00e9t\u00e9 autoris\u00e9e par la Food and Drug Administration (FDA) am\u00e9ricaine, et \u00e9value l\u2019inocuit\u00e9, la tol\u00e9rabilit\u00e9 et le profil pharmacocin\u00e9tique du FTX-101 lorsqu\u2019il est administr\u00e9 \u00e0 des volontaires sains. Cette \u00e9tude est randomis\u00e9e, en double aveugle, contr\u00f4l\u00e9e par placebo et elle comprend deux parties. Dans la premi\u00e8re partie, 40 sujets sains recevront une dose ascendante unique (SAD) de FTX-101 ou de placebo, tandis que dans la deuxi\u00e8me partie, 24 sujets recevront des doses ascendantes multiples (MAD), de FTX-101 ou de placebo pendant 14 jours.<\/p>\n\n\n\n
\n“Le lancement de cette \u00e9tude est une \u00e9tape importante pour notre soci\u00e9t\u00e9 car elle repr\u00e9sente une avanc\u00e9e majeure dans la recherche du premier traitement permettant d\u2019am\u00e9liorer la vie des personnes atteintes de neuropathie optique chronique. Le d\u00e9veloppement clinique du FTX-101 s\u2019appuie sur de nombreuses preuves pr\u00e9cliniques d\u00e9montrant les effets de ce compos\u00e9 dans des mod\u00e8les de maladies autoimmunes avec demy\u00e9linisation et nous sommes impatients de partager les donn\u00e9es de cette \u00e9tude de phase 1 au cours du premier semestre 2025.”<\/p>\n\n\n\n
– Philippe Douville, PDG de Find<\/p>\n<\/blockquote>\n\n\n\n
CONTACT INVESTISSEUR
Argot Partners
Sam Martin
646-233-4302<\/a>
Find@argotpartners.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Find Th\u00e9rapeutiques a annonc\u00e9 aujourd\u2019hui le d\u00e9but de son \u00e9tude clinique de phase 1 avec l\u2019administration du FTX-101 chez des volontaires sains. FTX-101 est un peptide th\u00e9rapeutique, premier de sa […]<\/p>\n","protected":false},"author":4,"featured_media":1925,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[41],"tags":[],"company":[110],"class_list":["post-1969","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualites-des-compagnies-du-portefeuille"],"yoast_head":"\n
Premier sujet trait\u00e9 dans le cadre de l\u2019\u00e9tude clinique de phase 1 du FTX-101 | adMare<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Premier sujet trait\u00e9 dans le cadre de l\u2019\u00e9tude clinique de phase 1 du FTX-101 | adMare\" \/>\n<meta property=\"og:description\" content=\"Find Th\u00e9rapeutiques a annonc\u00e9 aujourd\u2019hui le d\u00e9but de son \u00e9tude clinique de phase 1 avec l\u2019administration du FTX-101 chez des volontaires sains. FTX-101 est un peptide th\u00e9rapeutique, premier de sa […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/premier-sujet-traite-dans-le-cadre-de-letude-clinique-de-phase-1-du-ftx-101\/\" \/>\n<meta property=\"og:site_name\" content=\"adMare\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-21T13:08:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-26T13:08:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/find-therapeutics-fr-1744304415.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1199\" \/>\n\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Earnscliffe Strategies\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Earnscliffe Strategies\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/premier-sujet-traite-dans-le-cadre-de-letude-clinique-de-phase-1-du-ftx-101\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/premier-sujet-traite-dans-le-cadre-de-letude-clinique-de-phase-1-du-ftx-101\\\/\"},\"author\":{\"name\":\"Earnscliffe Strategies\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/person\\\/bd78e975574bdbf66541602c00a312da\"},\"headline\":\"Premier sujet trait\u00e9 dans le cadre de l\u2019\u00e9tude clinique de phase 1 du FTX-101\",\"datePublished\":\"2024-10-21T13:08:32+00:00\",\"dateModified\":\"2026-06-26T13:08:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/premier-sujet-traite-dans-le-cadre-de-letude-clinique-de-phase-1-du-ftx-101\\\/\"},\"wordCount\":333,\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/premier-sujet-traite-dans-le-cadre-de-letude-clinique-de-phase-1-du-ftx-101\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/find-therapeutics-fr-1744304415.png\",\"articleSection\":[\"Actualit\u00e9s des compagnies du portefeuille\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/premier-sujet-traite-dans-le-cadre-de-letude-clinique-de-phase-1-du-ftx-101\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/premier-sujet-traite-dans-le-cadre-de-letude-clinique-de-phase-1-du-ftx-101\\\/\",\"name\":\"Premier sujet trait\u00e9 dans le cadre de l\u2019\u00e9tude clinique de phase 1 du FTX-101 | adMare\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/premier-sujet-traite-dans-le-cadre-de-letude-clinique-de-phase-1-du-ftx-101\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/premier-sujet-traite-dans-le-cadre-de-letude-clinique-de-phase-1-du-ftx-101\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/find-therapeutics-fr-1744304415.png\",\"datePublished\":\"2024-10-21T13:08:32+00:00\",\"dateModified\":\"2026-06-26T13:08:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/premier-sujet-traite-dans-le-cadre-de-letude-clinique-de-phase-1-du-ftx-101\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/premier-sujet-traite-dans-le-cadre-de-letude-clinique-de-phase-1-du-ftx-101\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/premier-sujet-traite-dans-le-cadre-de-letude-clinique-de-phase-1-du-ftx-101\\\/#primaryimage\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/find-therapeutics-fr-1744304415.png\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/find-therapeutics-fr-1744304415.png\",\"width\":1199,\"height\":628},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/premier-sujet-traite-dans-le-cadre-de-letude-clinique-de-phase-1-du-ftx-101\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News & Events\",\"item\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/news-events\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"News & Insights\",\"item\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/news-events\\\/news-insights\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Premier sujet trait\u00e9 dans le cadre de l\u2019\u00e9tude clinique de phase 1 du FTX-101\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/\",\"name\":\"adMare\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#organization\",\"name\":\"adMare\",\"url\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"width\":915,\"height\":337,\"caption\":\"adMare\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/person\\\/bd78e975574bdbf66541602c00a312da\",\"name\":\"Earnscliffe Strategies\",\"url\":\"#\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Premier sujet trait\u00e9 dans le cadre de l\u2019\u00e9tude clinique de phase 1 du FTX-101 | adMare","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"Premier sujet trait\u00e9 dans le cadre de l\u2019\u00e9tude clinique de phase 1 du FTX-101 | adMare","og_description":"Find Th\u00e9rapeutiques a annonc\u00e9 aujourd\u2019hui le d\u00e9but de son \u00e9tude clinique de phase 1 avec l\u2019administration du FTX-101 chez des volontaires sains. FTX-101 est un peptide th\u00e9rapeutique, premier de sa […]","og_url":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/premier-sujet-traite-dans-le-cadre-de-letude-clinique-de-phase-1-du-ftx-101\/","og_site_name":"adMare","article_published_time":"2024-10-21T13:08:32+00:00","article_modified_time":"2026-06-26T13:08:32+00:00","og_image":[{"width":1199,"height":628,"url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/find-therapeutics-fr-1744304415.png","type":"image\/png"}],"author":"Earnscliffe Strategies","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Earnscliffe Strategies","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/premier-sujet-traite-dans-le-cadre-de-letude-clinique-de-phase-1-du-ftx-101\/#article","isPartOf":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/premier-sujet-traite-dans-le-cadre-de-letude-clinique-de-phase-1-du-ftx-101\/"},"author":{"name":"Earnscliffe Strategies","@id":"https:\/\/admarebio.com\/fr\/#\/schema\/person\/bd78e975574bdbf66541602c00a312da"},"headline":"Premier sujet trait\u00e9 dans le cadre de l\u2019\u00e9tude clinique de phase 1 du FTX-101","datePublished":"2024-10-21T13:08:32+00:00","dateModified":"2026-06-26T13:08:32+00:00","mainEntityOfPage":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/premier-sujet-traite-dans-le-cadre-de-letude-clinique-de-phase-1-du-ftx-101\/"},"wordCount":333,"publisher":{"@id":"https:\/\/admarebio.com\/fr\/#organization"},"image":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/premier-sujet-traite-dans-le-cadre-de-letude-clinique-de-phase-1-du-ftx-101\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/find-therapeutics-fr-1744304415.png","articleSection":["Actualit\u00e9s des compagnies du portefeuille"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/premier-sujet-traite-dans-le-cadre-de-letude-clinique-de-phase-1-du-ftx-101\/","url":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/premier-sujet-traite-dans-le-cadre-de-letude-clinique-de-phase-1-du-ftx-101\/","name":"Premier sujet trait\u00e9 dans le cadre de l\u2019\u00e9tude clinique de phase 1 du FTX-101 | adMare","isPartOf":{"@id":"https:\/\/admarebio.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/premier-sujet-traite-dans-le-cadre-de-letude-clinique-de-phase-1-du-ftx-101\/#primaryimage"},"image":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/premier-sujet-traite-dans-le-cadre-de-letude-clinique-de-phase-1-du-ftx-101\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/find-therapeutics-fr-1744304415.png","datePublished":"2024-10-21T13:08:32+00:00","dateModified":"2026-06-26T13:08:32+00:00","breadcrumb":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/premier-sujet-traite-dans-le-cadre-de-letude-clinique-de-phase-1-du-ftx-101\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/premier-sujet-traite-dans-le-cadre-de-letude-clinique-de-phase-1-du-ftx-101\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/premier-sujet-traite-dans-le-cadre-de-letude-clinique-de-phase-1-du-ftx-101\/#primaryimage","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/find-therapeutics-fr-1744304415.png","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/find-therapeutics-fr-1744304415.png","width":1199,"height":628},{"@type":"BreadcrumbList","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/premier-sujet-traite-dans-le-cadre-de-letude-clinique-de-phase-1-du-ftx-101\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/admarebio.com\/fr\/"},{"@type":"ListItem","position":2,"name":"News & Events","item":"https:\/\/admarebio.com\/fr\/news-events\/"},{"@type":"ListItem","position":3,"name":"News & Insights","item":"https:\/\/admarebio.com\/fr\/news-events\/news-insights\/"},{"@type":"ListItem","position":4,"name":"Premier sujet trait\u00e9 dans le cadre de l\u2019\u00e9tude clinique de phase 1 du FTX-101"}]},{"@type":"WebSite","@id":"https:\/\/admarebio.com\/fr\/#website","url":"https:\/\/admarebio.com\/fr\/","name":"adMare","description":"","publisher":{"@id":"https:\/\/admarebio.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/admarebio.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/admarebio.com\/fr\/#organization","name":"adMare","url":"https:\/\/admarebio.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/admarebio.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","width":915,"height":337,"caption":"adMare"},"image":{"@id":"https:\/\/admarebio.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/admarebio.com\/fr\/#\/schema\/person\/bd78e975574bdbf66541602c00a312da","name":"Earnscliffe Strategies","url":"#"}]}},"_links":{"self":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts\/1969","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/comments?post=1969"}],"version-history":[{"count":1,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts\/1969\/revisions"}],"predecessor-version":[{"id":1970,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts\/1969\/revisions\/1970"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/media\/1925"}],"wp:attachment":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/media?parent=1969"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/categories?post=1969"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/tags?post=1969"},{"taxonomy":"company","embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/company?post=1969"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}